Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
IQVIA is the world's largest contract research organization (CRO) and healthcare data analytics provider, serving pharmaceutical and biotech clients across 100+ countries. The company combines clinical trial management services (Technology & Analytics Solutions segment, ~$8B revenue) with real-world data/commercial insights (R&D Solutions segment, ~$8B revenue), benefiting from secular growth in drug development outsourcing and data-driven healthcare decision-making. Competitive moat stems from proprietary longitudinal patient databases covering 1+ billion anonymized patient records and deep embedded relationships with top 50 pharma companies.
IQVIA monetizes through multi-year service contracts with pharmaceutical, biotech, and medical device companies. Clinical trial contracts are typically cost-plus or fixed-fee arrangements with 3-5 year durations, generating recurring revenue as trials progress through phases. Data analytics products are sold via subscription licenses to proprietary databases (MIDAS sales data, longitudinal patient claims) with high gross margins (60-70% estimated). Pricing power derives from switching costs—clients embed IQVIA's data infrastructure into regulatory submissions and commercial strategies. The company benefits from operating leverage as incremental data sales require minimal marginal cost, while scale advantages in global site networks (14,000+ investigator relationships) create barriers to entry for smaller CROs.
Contracted backlog growth and book-to-bill ratio (indicates future revenue visibility; backlog typically $25B+ representing 18+ months of revenue)
Pharmaceutical R&D spending trends and clinical trial starts (IQVIA captures ~15-20% of outsourced CRO market; industry spending ~$200B annually)
Technology & Analytics segment organic growth rate (higher-margin business; investors focus on double-digit growth sustainability)
Large contract wins or losses with top 20 pharma clients (top 10 clients represent ~30% of revenue; single contract can be $100M+ annually)
Margin expansion trajectory in R&D Solutions (labor utilization rates, offshore delivery mix, automation of trial monitoring)
Pharmaceutical pricing pressure and regulatory reforms (e.g., Medicare negotiation, international reference pricing) could reduce pharma profitability and R&D budgets, though drug development outsourcing trend (currently 50-60% of trials outsourced vs 40% a decade ago) provides offset
Technology disruption from AI-enabled trial design and synthetic control arms could commoditize portions of clinical trial services, compressing pricing on standardized protocols; decentralized trials reduce need for site network infrastructure
Data privacy regulations (GDPR, HIPAA expansions) increase compliance costs and could restrict access to real-world evidence databases that underpin analytics business
Market share pressure from specialized CROs (Syneos, PPD/Thermo Fisher, Labcorp Drug Development) competing on therapeutic expertise or regional presence; top 5 CROs control 40% of market, leaving fragmented competition
In-house capabilities expansion by large pharma (e.g., building proprietary data platforms, re-insourcing Phase I trials) could reduce outsourcing penetration, though trend has been toward greater outsourcing for 15+ years
Technology platform competition from emerging players (e.g., Science 37 for decentralized trials, Flatiron/Roche for oncology real-world data) targeting high-growth niches
Elevated leverage at 2.49x Debt/Equity (~3.5x Net Debt/EBITDA estimated) limits financial flexibility and creates refinancing risk if credit markets tighten; $9.5B gross debt with staggered maturities through 2028-2030
Below-benchmark current ratio of 0.75 indicates working capital strain, typical for CRO business model (deferred revenue liability from upfront client payments offsets receivables), but limits liquidity cushion during downturns
Acquisition integration risk from $15B+ in historical M&A (IMS Health-Quintiles merger 2016, plus 20+ tuck-ins); goodwill represents ~40% of assets, creating impairment risk if growth disappoints
low-to-moderate - Pharmaceutical R&D spending is relatively recession-resistant as drug development timelines span 7-10 years and regulatory milestones drive investment decisions more than GDP growth. However, biotech funding (20-25% of IQVIA revenue) correlates with venture capital availability and IPO markets, creating modest cyclical exposure. Commercial analytics demand can soften if pharma clients face pricing pressure or launch delays. Historical evidence: CRO revenue growth remained positive through 2008-2009 recession, though growth rates decelerated from mid-teens to mid-single-digits.
Rising rates create moderate headwinds through two channels: (1) Higher financing costs on $9.5B gross debt (mix of fixed/floating; estimated 50% floating exposure creates ~$50M annual EBIT impact per 100bps rate increase), and (2) Biotech funding constraints as venture capital becomes more expensive and risk-off sentiment reduces IPO activity, potentially reducing small/mid-cap pharma trial starts by 10-15%. Valuation multiple compression also occurs as investors rotate from growth to value. However, large-cap pharma clients (60% of revenue) are less rate-sensitive given strong balance sheets.
Moderate exposure through biotech client creditworthiness. IQVIA extends payment terms to smaller biotech clients (often 60-90 days) and faces occasional write-offs when undercapitalized biotechs fail mid-trial. Estimated 5-10% of backlog represents higher-risk biotech counterparties. Tightening credit conditions reduce biotech access to capital markets, potentially leading to trial cancellations or payment delays. The company mitigates risk through milestone-based billing and upfront deposits for smaller clients.
value-growth hybrid - The stock attracts investors seeking exposure to secular healthcare outsourcing trends (5-7% organic growth) with improving free cash flow generation (7.3% FCF yield above S&P 500 average). Recent 24% drawdown creates value opportunity for investors believing margin expansion story (14% operating margin has room to reach 16-17% as higher-margin analytics scales). Dividend absent, so income investors avoid. Private equity-style financial engineering (leverage, M&A, cost optimization) appeals to event-driven funds. Not a pure growth stock given mid-single-digit revenue growth, but growth-at-reasonable-price (GARP) investors find 1.7x P/S attractive relative to 20%+ ROE.
moderate - Healthcare services stocks typically exhibit beta of 0.8-1.1 to broader market. IQVIA's diversified revenue base (100+ countries, 1000+ clients) reduces idiosyncratic volatility, but leverage amplifies downside during risk-off periods. Recent 24% decline suggests elevated volatility amid biotech funding concerns and interest rate sensitivity. Historical standard deviation likely 25-35% annualized, below high-growth software (40-50%) but above defensive healthcare (15-25%).
